Evidence map›Paper›PMID 30073002›Full record

ArticleFrontiers in immunology2018

HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation.

Isaac Rosado-Sánchez, Inés Herrero-Fernández, Miguel Genebat, Jorge Del Romero, Melchor Riera, Daniel Podzamczer, Julián Olalla, Francesc Vidal, Mª Angeles Muñoz-Fernández, Manuel Leal and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Pathological Proliferation of CD4Infection and drug resistance · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Isaac Rosado-SánchezInstitute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
Inés Herrero-FernándezInstitute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
Miguel GenebatInstitute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
Jorge Del RomeroCentro de Salud Sandoval, Madrid, Spain.
Melchor RieraSon Espases University Hospital, Palma de Mallorca, Spain.
Daniel PodzamczerBellvitge University Hospital, L'Hospitalet de Llobregat, Spain.
Julián OlallaCosta del Sol Hospital, Marbella, Spain.
Francesc VidalJoan XXIII University Hospital, IISPV, Rovira I Virgili University, Tarragona, Spain.
Mª Angeles Muñoz-FernándezSection Immunology, Laboratorio InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Manuel LealInstitute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
Yolanda M PachecoInstitute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
Instituto de Biomedicina de Sevilla · ESUniversidad de Sevilla · ESBellvitge University Hospital · ESHospital Costa del Sol · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario Son Espases · ESHospital Universitario Virgen del Rocío · ESInstitut d'Investigació Sanitària Pere Virgili · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHIV-infected subjects with suboptimal CD4 restoration despite suppressive combined antiretroviral treatment (cART) (immunodiscordant subjects) have been classically characterized after a variable period of time under cART. Recently, we have reported that an increased frequency of proliferating CD4 T-cells in these subjects is already present before the cART onset. The potential contribution of peripheral compensatory homeostatic proliferation (HP) is yet unknown. We aimed to analyze the expression of HP-related cellular markers on CD4 T-cells of immunodiscordant subjects before cART.

methodsWe analyzed the expression of OX40 and α4β7 on peripheral CD4 T-cells from immunodiscordant and control subjects (

resultsImmunodiscordant subjects showed increased levels of OX40 and α4β7 on CD4 T-cells before cART initiation. While the cART tended to reduce these levels, immunodiscordant subjects still maintained comparatively higher levels of OX40 and α4β7 after 24 months under suppressive cART. These HP-related markers were upregulated

conclusionOur results are compatible with exacerbated HP processes in immunodiscordant subjects, already before the cART onset.

Indexed as

CD4 T-cell homeostasisHIVhomeostatic parametershomeostatic proliferationimmunodiscordant response to combined antiretroviral treatmentlow CD4 recoveryOX40α4β7

Identifiers

PMID30073002
PMCPMC6058017
OpenAlexW2881769165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.